Diuretic Resistance in Advanced Heart Failure: A Literature Review

Anita Surya Santoso, Mohammad Saifur Rohman, Indra Prasetya, Budi Satrijo

Brawijaya Cardiovascular Research Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.

ARTICLE INFO
Keywords:
Advanced heart failure;
Loop diuretic;
Congestion;
Diuretic resistance

ABSTRACT
Background: Diuretic resistance is a common problem issue in acute decompensation of advanced heart failure. Diuretic therapy is mainly described in the current guidelines for HF treatment. However, diuretic resistance is a common problem issue in acute decompensation of advanced chronic heart failure (ACHF) patients and established prognostic factor.

Objective: In this review, we will discuss how to diagnose the advanced heart failure and the underlying mechanism of diuretic resistance in heart failure patients. We also describe pharmacological and non-pharmacological strategies to overcome this issue.

Discussion: Advanced heart failure (HF) is used to characterize patients in HF with severe symptoms, recurrent decompensation and severe cardiac dysfunction. Most of HF hospitalization are due to signs and symptoms of fluid overload. Recurrent congestion could worsen patients outcomes. Loop diuretics are recommended for the treatment of congestion in ACHF patients. However, diuretic resistance is a common problem issue in acute decompensation of advanced chronic heart failure (ACHF) patients and established prognostic factor. The pathophysiology of diuretic resistance is very complex, and several etiologies may be involved. It derives from multiple factors, including reduced delivery of the diuretic to its luminal site of action, neurohormonal activation, tubular compensatory adaptation, and drug interactions.

Conclusion: Diuretic resistance has emerged as an independent factor behind worse HF patient outcomes, namely in-hospital worsening, early post-discharge mortality, and rehospitalizations. Once the diuretic resistance has been treated successfully, the treatment of advanced HF should be optimized in order to reduce further morbidity and mortality.

1. Introduction

Heart failure (HF) is a clinical syndrome characterized by typical symptoms such as breathlessness, ankle swelling, and fatigue. Signs may be accompanied by increased jugular venous pressures (JVP), pulmonary crackles, and peripheral edema which can cause a structural and/or functional cardiac abnormality, resulting in reduced cardiac output and/or increased intracardiac pressures at rest or during stress. Advanced HF is used to characterize patients with severe symptoms, recurrent decompensation, and severe cardiac dysfunction problem.1

The prevalence of HF is approximately 1-2% of the adult population in developed countries and increase more than 10% among people >70 years of age, whereas estimated the prevalence of patients with advanced heart failure is about 1% until 10% of the overall heart failure population. It was predicted to increase because of the growing number of patients with heart failure and their better treatment and survival rate.2

Most of the HF hospitalizations are due to signs and symptoms of fluid overload. Recurrent congestion could worsen patients outcomes. Loop diuretics are recommended for the treatment of congestion in heart failure patient. Diuretic therapy is mainly described in the current guidelines for HF treatment. However, diuretic resistance is a common problem issue in acute decompensation of advance chronic heart failure (ACHF) patients and established prognostic factor. Some early report estimated the prevalence of diuretic resistance about 20%-30% in HF patients population.3

In this review, we will discuss how to diagnose the advance heart failure and the underlying mechanism of diuretic resistance in HF patients. We also describe pharmacological and non-pharmacological strategies to overcome this issue.

2. Discussion

2.1 Advance Heart Failure

https://doi.org/10.21776/ub.hsj.2021.002.01.02
Received 25 January 2021; Received in revised form 1 February 2021; Accepted 15 February 2021
Available online 28 February 2021
2721-9976 / ©UB Press. All rights reserved.
2.2.1 Definition of Advanced Heart Failure

The definition of advanced HF is evolved over time to provide more comprehensive criteria for clinicians to diagnose. According to ESC 2018 guidelines, advanced HF is characterized by severe and persistent symptoms of heart failure (NYHA class III or IV), severe left ventricular dysfunction (LVEF ≤ 30%), and one or more signs of congestion (e.g., jugular venous pressure elevation) and/or extracellular fluid accumulation that result from increased filling pressures. These signs and symptoms include fluid retention, oedema, dyspnoea at rest or on minimal activity, elevated jugular venous pressure (JVP), peripheral and hepatic venous congestion, pulmonary congestion and arrhythmias, repeated hospital admissions, and intractable symptoms. It is important to note that the definition of advanced HF is evolving over time and may vary across different guidelines.

2.2.2 Detecting Congestion in Heart Failure

Congestion in HF can be defined as signs and symptoms of extracellular fluid accumulation that result in increased cardiac filling pressures. Filling pressures are the integrated result of the cardiac systolic and diastolic function, volume status, and venous capacitance/compliance. HF with increased neurohumoral activation induces systemic congestion, indicative chest X-ray and measurement of elevated NPs allows for the diagnosis of congestion.

2.3 Mechanism of Action of Diuretics in Heart Failure

As blood flows through the kidney, it passes into glomerular capillaries located within the cortex (outer zone of the kidney). These glomerular capillaries are highly permeable to water and electrolytes. Glomerular capillary hydrostatic pressure drives (filters) water and electrolytes into Bowman’s space and into the proximal convoluting tubule (PCT). About 20% of the plasma that enters the glomerular capillaries are filtered (termed filtration fraction). The PCT, which lies within the cortex, is the site of sodium, water, and bicarbonate transport from the filtrate (urine), across the tubule wall, and into the interstitium of the cortex. About 65-70% of the filtered sodium is removed from the urine found within the PCT (this is termed sodium reabsorption). This sodium is reabsorbed isosmotically, meaning that every molecule of sodium that is reabsorbed is accompanied by a molecule of water. As the tubule dives into the medulla or middle zone of the kidney, the tubule becomes narrower and forms a loop (Loop of Henle) that reenters the cortex as the thick ascending limb (TAL) that travels back to near the glomerulus. Because the interstitium of the medulla is very hypotonic and the Loop of Henle is permeable to water, water is reabsorbed from the Loop of Henle and into the medullary interstitium. This loss of water concentrates the urine within the Loop of Henle.

The TAL, which is impermeable to water, has a cotransport system that reabsorbs sodium, potassium, and chloride at a ratio of 1:1:2. Approximately 25% of the sodium load of the original filtrate is reabsorbed at the TAL. From the TAL, the urine flows into the distal convoluting tubule (DCT), which is another site of sodium transport (~5% via a sodium- chloride cotransporter) into the cortical interstitium (the DCT is also impermeable to water). Finally, the tubule dives back into the medulla as the collecting duct and then into the renal pelvis, where it joins with other collecting ducts to exit the kidney as the ureter. The distal segment of the DCT and the upper collecting duct has a transporter that reabsorbs sodium (about 1-2% of filtered load) in exchange for potassium and hydrogen ion, which are excreted into the urine. It is important to note two things about this transporter. First, its activity is dependent on the tubular concentration of sodium so that when sodium is high, more sodium is reabsorbed, and more potassium and hydrogen ion are excreted. Second, this transporter is regulated by aldosterone, which is a mineralocorticoid hormone secreted by the adrenal cortex. Increased aldosterone stimulates the reabsorption of sodium, which also increases the loss of potassium and hydrogen ion to the urine. Finally, water is reabsorbed in the collected duct through special pores that are regulated by antidiuretic hormone, which is released by the posterior pituitary. ADH increases the permeability of the collecting duct to water, which leads to increased water reabsorp.
Diuretic drugs will increase urine output by the kidney. This is accomplished by altering how the kidney handles sodium. If the kidney excretes more sodium, then water excretion will also increase. Most diuretics produce diuresis by inhibiting the reabsorption of sodium at different segments of the renal tubular system. Sometimes a combination of two diuretics is given because this can be significantly more effective than either compound alone (synergistic effect). The reason for this is that one nephron segment can compensate for altered sodium reabsorption at another nephron segment; therefore, blocking multiple nephron sites significantly enhances efficacy.

- **Loop Diuretics**

Loop diuretic action by inhibit the sodium-potassium-chloride cotransporter in the thick ascending limb. This transporter normally reabsorbs about 25% of the sodium load; therefore, inhibition of this pump can lead to a significant increase in the distal tubular concentration of sodium, reduced hypertonicity of the surrounding interstitium, and less water reabsorption in the collecting duct. This altered handling of sodium and water leads to both diuresis (increased water loss) and natriuresis (increased sodium loss). By acting on the thick ascending limb, which handles a significant fraction of sodium reabsorption, loop diuretics are very powerful diuretics. These drugs also induce renal synthesis of prostaglandins, which contributes to their renal action, including the increase in renal blood flow and redistribution of renal cortical blood flow.

- **Thiazide Diuretics**

Thiazide diuretics, which are the most commonly used diuretic, inhibit the sodium-chloride transporter in the distal tubule. Because this transporter normally only reabsorbs about 5% of filtered sodium, these diuretic are less efficacious than loop diuretics in producing diuresis and natriuresis. Nevertheless, they are sufficiently powerful to satisfy many therapeutic needs requiring a diuretic. Their mechanism depends on renal prostaglandin production.

Because loop and thiazide diuretics increase sodium delivery to the distal segment of the distal tubule, this increases potassium loss (potentially causing hypokalemia) because the increase in distal tubular sodium concentration stimulates the aldosterone-sensitive sodium pump to increase sodium reabsorption in exchange for potassium and hydrogen ion, which are lost to the urine. The increased hydrogen ion loss can lead to metabolic alkalosis. Part of the loss of potassium and hydrogen ion by loop and thiazide diuretics results from activation of the RAA (renin-angiotensin-aldosterone) system that occurs because of reduced blood volume and arterial pressure. Increased aldosterone stimulates sodium reabsorption and increases potassium and hydrogen ion excretion into the urine.

- **Potassium-sparing Diuretics**

There is a third class of diuretic that is referred to as potassium-sparing diuretics. Unlike loop and thiazide diuretics, some of these drugs do not act directly on sodium transport. Some drugs in this class antagonize the actions of aldosterone (aldosterone receptor antagonists) at the distal segment of the distal tubule. This causes more sodium (and water) to pass into the collecting duct and be excreted in the urine. They are called K⁺-sparring diuretics because they do not produce hypokalemia like the loop and thiazide diuretics. The reason for this is that by inhibiting aldosterone-sensitive sodium reabsorption, less potassium and hydrogen ion are exchanged for sodium by this transporter, and therefore less potassium and hydrogen are lost to the urine. Other potassium-sparing diuretics directly inhibit sodium channels associated with the aldosterone-sensitive sodium pump and it have similar effects on potassium and hydrogen ion as the aldosterone antagonists. Their mechanism depends on renal prostaglandin production. Because this class of diuretic has relatively weak effects on overall sodium balance, they are often used in conjunction with thiazide or loop diuretics to help prevent hypokalemia.

- **Carbonic Anhydrase Inhibitors**

Carbonic anhydrase inhibitors inhibit the transport of bicarbonate out of the proximal convoluted tubule into the interstitium, which leads to less sodium reabsorption at this site and, therefore, greater sodium, bicarbonate and water loss in the urine. These are the weakest of the diuretics and seldom used in cardiovascular disease. Their main use is in the treatment of glaucoma.

2.4 Diuretic Resistance

The general definition refers to the failure to achieve effective congestion relief despite appropriate or escalating doses of diuretics. It can be defined by inadequate response to diuretic therapy (e.g., failure to lose 0.5-1kg of weight per day) when the following measures are ensured: the absence of third space overload with intravascular volume depletion, dietary salt restriction (fractional excretion of sodium <2%) and discontinuation of nonsteroidal anti-inflammatory drugs. Some early reports estimated the prevalence of diuretic resistance to be 20%-30% among HF patients. However, the lack of a formal definition makes it impossible to properly assess the numbers. The pathophysiology of diuretic resistance is very complex, and several etiologies may be involved. It derives from multiple factors, including reduced delivery of the diuretic to its luminal site of action, neurohormonal activation, tubular compensatory adaptation, and drug interactions.

- **Reduced Delivery of the Diuretic to its site of Action**

Reduced delivery of the diuretic to its site of action is closely related to its decreased bioavailability. In HF patients, increased peripheral and bowel wall edema leads to reduced absorption of the diuretic, with a more marked effect when oral furosemide is used. HF itself, as well as concurrent chronic kidney disease (CKD) (urate and other competing organic acids), may lead to decreased glomerular filtration rate, which in turn leads to impaired secretion of diuretics by the organic acid transporter into the proximal tubule. Reduced glomerular filtration rate can, therefore, reduce delivery or reduce the active secretion of loop diuretics into their site of action. Moreover, CKD has been proposed as a contributing factor to the development of HF overall, regardless of left ventricular ejection fraction. CKD leads to volume retention, altered calcium-phosphate metabolism, hyperparathyroidism, vitamin D deficiency, anemia, and the accumulation of uremic toxins.

Renal dysfunction caused by intra-abdominal hypertension and cardiorenal syndromes is also a plausible mechanism of diuretic resistance through venous congestion. Intra-abdominal hypertension relief improves renal perfusion, renal filtration, and diuresis. It is usually present in up to 60% of acutely decompensated HF patients. It is very important to emphasize the need to detect third-space overload
as opposed to intravascular overload because both the kidneys and diuretic therapy can only act in vascular overload.4

Persistent diuretic use in patients who are already suffering from intravascular volume depletion further activates the renin-angiotensin-aldosterone (RAA) axis and makes diuretic resistance dependent on renal blood flow. Sodium and chloride measurements may indicate when the vascular volume has been optimized because they decrease as euvolemia approaches. These may serve as more reliable markers of decongestion as opposed to the clinical signs and symptoms traditionally used to guide decongestive therapy.7 Clinical signs and symptoms lack sensitivity and specificity but do raise the need for further clinical evaluation. Natriuretic peptides are helpful for diagnosis and prognosis but lack the power to properly monitor volume status. Newer approaches point to quantitative blood volume analysis as a means to differentiate hypervolemia profiles. Appropriate profiling of volume overload in HF, according to blood volume, has therapeutic implications and may aid patients with diuretic resistance, redirecting them to other forms of decongestion.4

Another mechanism of diuretic activity impairment involves increased reabsorption of sodium and chloride in the proximal tubule, leading to decreased delivery of these substrates to the distal areas of the nephron where loop diuretics act. This mechanism causes diuretic resistance through decreased substrate availability to the sodium-potassium-chloride cotransport system.9

Albumin levels also correlate to diuretic action because they are high-affinity albumin-binding molecules more than 90%. Hypoaalbuminemia increases the drug distribution volume and prevents suitable kidney delivery. On the other hand, high levels of albuminuria decrease loop diuretic delivery. Increased urine albumin binds to diuretics, preventing their ligation to the sodium-potassium-chloride receptors and thus impairing their action.20

**Neurohormonal Activation**

Neurohormonal activation is strongly related to RAA axis upregulation. Loop diuretics can activate the RAA axis through a variety of mechanisms. They induce renin secretion through the direct blockade of the macula densa sodium-potassium-chloride cotransport system, thus leading to increased renin and aldosterone in a volume-independent pathway. Furthermore, diuretics induce renal prostacyclin production, which increases renin secretion. Finally, diuretics induce volume contraction, thus activating renin secretion through vascular stimulation. RAA axis activation eventually leads to increased sodium reabsorption, prompting the onset of post-diuretic sodium retention and the braking phenomenon.21

Post-diuretic sodium retention is one of the processes through which diuretic resistance may be established, and it arises as soon as the concentration of diuretic in the tubular fluid drops below the therapeutic threshold. A negative net sodium balance in the 24 hours between natriuresis and post-diuretic sodium retention may not be achieved in the event of dietary non-compliance, rendering the diuretic effect insignificant. The braking phenomenon, on the other hand, is defined as the decrease in diuresis volume after multiple same-dose administrations of diuretic. This is linked to RAA axis activation and compensatory changes in the nephron.9

**Tubular Compensatory Readaptation**

Tubular readaptation is another mechanism that helps explain the reduced diuretic response. Owing to the above-mentioned activation of the RAA axis, as well as the braking phenomenon, proximal tubular reabsorption arises, leading to increased sodium uptake in this area of the nephron. Simultaneously, the chronic use of loop diuretics, which inhibit sodium uptake in the loop of Henle, leads to increased sodium delivery to the distal tubular system, resulting in compensatory hyperplasia and hypertrophy. This means that the patient would retain more sodium and thus water than a diuretic-naïve patient. This resistance mechanism can be overcome using a sequential nephron blockade with thiazide diuretics.4

**Drug Interactions**

Some drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs), can reduce the effect of diuretics. NSAIDs may cause diuretic resistance in a number of ways, particularly decreased prostaglandin synthesis, decreased renal vasodilation, increased renal reabsorption in areas of the nephron other than the loop of Henle and hypertension.9

Evidence regarding the effect of low-dose aspirin (<1 mg/kg/day) on a diuretic response, in particular, is more scarce and controversial. A previous study reported that chronic low-dose aspirin could profoundly affect platelet prostaglandin production without affecting diuretic-stimulated renal prostacyclin production or plasma renin activity. However, Jhund et al. demonstrated that the dilatation

---

**Figure 1. Sites and Mode of Action and Effects on Sodium Reabsorption in the Nephron of Different Diuretics**

- 65% sodium reabsorption (In HF reabsorption up to 75%)
- Early DCT
- Late DCT
- Loop diuretics
- Microvascular and receptor antagonists
on vena could occur following furosemide administration could be inhibited by both high and low dose-aspirin. Furthermore, Hall noted an important reduction in the need for diuretics when daily aspirin administration was stopped. There is also some evidence that aspirin, even at a low dose, may neutralize the favorable effects of angiotensin-

2.4.2 Management for Diuretic Resistance

• **Salt Restriction**

  Dietary sodium restriction is a key determinant of diuretic efficacy. When dietary sodium intake is high, post-diuretic sodium retention compensates almost entirely for the loop-diuretic-induced sodium loss. Conversely, if sodium intake is restricted, post-diuretic sodium retention is minimized, resulting in a negative fluid and sodium balance. Thus, restricting sodium intake to less than 100 mEq/day mitigates the effect of post-diuretic sodium retention and helps achieve a negative sodium balance. A 24-hour urinary sodium excretion of more than 100 mEq/day or fractional excretion of sodium value >2% indicates non-compliance with sodium restriction and rules out true diuretic resistance.9

• **Discontinue concomitant use of nonsteroidal anti-inflammatory drugs**

  Concomitant use of NSAIDs is a major cause of diuretic failure, and discontinuing them can significantly improve diuretic effectiveness.9

• **Establish the Effective Single Dose**

  Diuretics have a dose-response curve, and the effect only begins once the diuretic level reaches a therapeutic threshold within the renal tubular lumen. In conditions such as CKD and cardiorenal syndrome, the dose-response curve shifts downwards and towards the right. This means that these patients need higher doses of loop diuretics to achieve the therapeutic drug level at the site of action. Diuretic doses below said threshold are ineffective, so a higher effective single loop diuretic dose is needed rather than administering an inadequate dose more frequently.4

  • **Increase the dose frequency of loop diuretics**

    Because most loop diuretics are short-acting, increasing the dose frequency can help overcome post-diuretic sodium retention and restore diuretic response.4

  • **Diuretic Substitution**

    Gastrointestinal absorption and the bioavailability of different diuretics belonging to the same class can vary considerably, and this could be a factor behind a poor response. Furosemide has a bioavailability of about 50%, whereas torsemide and bumetanide have almost completed absorption (80-100%). At times, replacing furosemide with comparable doses of bumetanide or torsemide can be enough to improve diuresis.5

  • **Intravenous Diuretics**

  ![](image.png)

  Figure 2. Mechanism of Diuretic Resistance in Heart Failure.11
Sometimes, administering diuretics intravenously instead of orally is all that is needed to improve diuresis. Oral absorption may be altered in the presence of gastrointestinal edema, gastroparesis, and delayed gastric emptying. Drug concentration at the site of diuretic action in the tubule lumen may be inadequate due to decompensated HF, renal hypoperfusion, or impaired secretion as a result of hypoalbuminemia.

Compared to bolus doses, continuous diuretic infusion may be more effective in improving diuresis. It may decrease fluctuations in intravascular volume, resulting in a more gradual and relatively constant hourly urine output and limiting the effect of post-diuretic sodium retention. Some studies found that furosemide administered as a continuous infusion was more effective than intermittent bolus doses since significantly less furosemide was required to produce the same diuresis and due to the elimination of a diuretic-free interval (during which compensatory sodium retention occurs). In the Diuretic Optimization Strategies Evaluation (DOSE) trial, there were no significant differences in patients’ global symptom assessment or in the change in renal function between the two strategies.

Table 1. Combination diuretic therapy

| Distal convoluted tubule diuretics | Proximal tubule diuretics | Potassium-sparing diuretics | Management of intraabdominal pressure |
|------------------------------------|--------------------------|-----------------------------|--------------------------------------|
| Metolazone 2.5-10 mg per os daily (duration or frequency adjusted based on the target weight) | Acetazolamide 250-375 mg daily or up to 500 mg intravenously | Spironolactone 100-200 mg daily | Intra-abdominal hypertension is defined as a sustained intra-abdominal pressure of 12 mmHg or above. Splanchnic and interstitial congestion may cause elevated intra-abdominal pressure in the absence of ascites in acute decompensated HF. In such patients, a rise in intra-abdominal pressure increases renal venous pressure, thereby reducing the transsept perfusion gradient and renal perfusion. Elevated intra-abdominal pressure also causes increased renal interstitial pressure that opposes net filtration pressure. Both contribute to renal impairment and diuretic resistance. When intravenous loop diuretic therapy fails, measuring intra-abdominal pressure is an inexpensive and minimally invasive procedure that rules out a diuretic resistance cause. If intra-abdominal hypertension or abdominal compartment syndrome (defined as a sustained intra-abdominal pressure of >20 mmHg, which is associated with new organ dysfunction) is identified, a reduction in intra-abdominal pressure by mobilizing third-space fluid can be achieved through a combination of diuretics, vasodilators and/or inotropes. Abundant ascites can be managed with paracentesis, ultrasound, or computer tomography guidance if needed. In certain patients, ultrafiltration (UF) may be appropriate. The therapeutic aim is to achieve an abdominal perfusion pressure (calculated as the mean arterial pressure minus the intra-abdominal pressure) of over 60 mmHg (with an intra-abdominal pressure of 5 to 7 mmHg), which signifies a favorable outcome (improvement in renal perfusion, renal filtration, and diuresis).

| Infusion with Albumin |
|-----------------------|
| Low doses of dopamine (<3 mcg/kg/min) selectively work on peripheral dopaminergic receptors resulting in vaso dilation in the renal, coronal, splanchnic, and cerebral circulations. Two recent trials of dopamine in acute HF - the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial and the Renal Optimization Strategies Evaluation (ROSE) trial - have shown no added benefit with the addition of dopamine to standard therapy with high-dose diuretics. Thus, on the basis of current data, dopamine has no role in nonhypotensive patients with acute HF. |

| Renal Dose Dopamine |
|---------------------|
| Nesiritide is a synthetic B-type natriuretic peptide (BNP) approved by the Food and Drug Administration for symptomatic relief due to its favorable effects on hemodynamics, dyspnea, and renal function. However, both the ROSE trial and ter Maaten et al. (2015) found no additive effect of using low-dose nesiritide added to diuretic therapy in terms of decongestion or improved renal function. Experimental research has shown that renal delivery of BNP had significantly greater beneficial effects than systemic delivery. It could be that a higher systemic dose is needed; however, the usage there of would increase the incidence of adverse effects such as hypotension. |

| Alternative Pharmacological Therapies |
|-------------------------------------|
| Vasopressin-2 receptor antagonists may promote aquarexis by blocking the effects of vasopressin on the vasopressin-2 receptors located in the collecting ducts, thus blocking the reabsorption of free water. This promotes water clearance without affecting sodium |
balance. In the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Torvastatin (EVEREST) trial, torvastatin at a dose of 30 mg once daily for a minimum of 60 days had no effect on total mortality or HF hospitalization when compared to placebo.

*Ultrafiltration*

UF is very effective at removing plasma fluid from blood across a semipermeable membrane that allows small molecules to pass through along its pressure gradient to the ultrafiltrate fluid. Small studies suggest that UF improves pulmonary and peripheral edema, lung function, and hemodynamics without adverse effects on renal function. The fluid removal rate is reevaluated using clinical assessment and serial hematocrit measurements to ensure appropriate vascular function, and hemodynamics without adverse effects on renal function.

The recent development of venovenous peripheral venous hematocrit measurements to ensure appropriate vascular compartment refill. The recent development of venovenous peripheral UF has positioned this technique as a potential alternative to loop diuretics in acute HF.

3. Conclusion

The pathophysiology of diuretic resistance is very complex, and several etiologies may be involved. It derives from multiple factors, including reduced delivery of the diuretic to its luminal site of action, neurohormonal activation, tubular compensatory adaptation, and drug interactions. Diuretic resistance has emerged as an independent factor behind worse HF patient outcomes, namely in-hospital worsening, early post-discharge mortality, and rehospitalizations. Once the diuretic resistance has been treated successfully, the treatment of advanced HF should be optimized in order to reduce further morbidity and mortality. So, it is important for clinicians to diagnose diuretic resistance in advanced heart failure in order to have comprehensive management.

4. Declaration

4.1. Ethics Approval and Consent to participate

Not applicable.

4.2. Consent for publication

Not applicable.

4.3. Availability of data and materials

Data used in our study were presented in the main text.

4.4. Competing interests

Not applicable.

4.5. Funding source

Not applicable.

4.6. Authors contributions

Idea/concept: MSR, ASS. Design: ASS. Control/supervision: MSR, QP, BS. Data collection/processing: ASS. Extraction/Analysis/interpretation: ASS. Literature review: MSR. Writing the article: ASS. Critical review: MSR. IP. BS. All authors have critically reviewed and approved the final draft and are responsible for the content and similarity index of the manuscript.

4.7. Acknowledgements

We thank to Brawijaya Cardiovascular Research Center.

References

1. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Testani JM, Tang WW, Orso F, Rossignol P, Metra M. The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology. European journal of heart failure. 2019 Feb;21(2):137-55.

2. Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filipatos G, Gustafsson F, Tsui S, Barge-Caballero E, De Jonge N, Frigerio M. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. European journal of heart failure. 2018 Nov;20(11):1505-35.

3. Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, Cook NR, Felker GM, Francis GS, Hauptman PJ, Havranek EP. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2012 Apr 17;125(15):1928-52.

4. Houston BA, Kalathiyi RJ, Kim DA, Zakaria S. Volume overload in heart failure: an evidence-based review of strategies for treatment and prevention. InMayo Clinic Proceedings 2015 Sep 1 (Vol. 90, No. 9, pp. 1247-1261). Elsevier.

5. Aziz, E.F., Alviar, C.L., Herzog, E., Cordova, J.P., Bastawrosse, J.H., Panidimu, C.K., Tojino, A., Park, T.S., Musat, D. and Kukin, M., 2011. Continuous infusion of furosemide combined with low-dose dopamine compared to intermittent boluses in acutely decompen-sated heart failure is less nephrotic and carries a lower readmis-sion at thirty days. Hellenic J Cardiol, 52(3), pp.227-235.

6. Ellison DH, Felker GM. Diuretic treatment in heart failure. New England Journal of Medicine. 2017 Nov 16;377(20):1964-75.

7. Frea S, Pidello S, Volpe A, Canovosigio FG, Galluzzo A, Bovolo V, Camarda A, Golizog P, D’Arcenoz F, Bergerone S, Rinaldi M. Diuretic treatment in high-risk acute decompensation of advanced chronic heart failure—bolus intermittent vs. continuous infusion of furose-mide: a randomized controlled trial. Clinical Research in Cardiolo-gy. 2019 Jun 29:1-9.

8. Di Somma S, Magrini L. Drug therapy for acute heart failure. Revista Española de Cardiología (English Edition). 2015 Aug 1;68(8):706-13.

9. Bowman BN, Nawarskas JJ, Anderson JR. Treating Diuretic Resistance. Cardiology in review. 2016 Sep;124(5):256-60.

10. Pham D, Grodin JL. Dilemmas in the dosing of heart failure drugs: titrating diuretics in chronic heart failure. Cardiac failure review. 2017 Nov;3(2):108.

11. Casu G, Merella P. Diuretic Therapy in Heart Failure–Current Approaches. European Cardiology Review. 2015 Jul;10(1):42.

12. Dohi K, Ito M. Novel diuretic strategies for the treatment of heart failure in Japan. Circulation Journal. 2014 Jul 25;78(8):1816-23.

13. Neuberg GW, Miller AB, O’Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M. Diuretic resistance predicts mortality in patients with advanced heart failure. American heart journal. 2002 Jul 1;144(1):31-8.

14. Felker GM, Ellison DH, Mullen WS, Cox ZL, Testani JM. Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2020 Mar 17;75(10):1178-95.

15. Clarke B. Cardiorenal Interactions, Diuretic Resistance, and Acute Heart Failure: Renal Response vs Renal Function. Canadian Journal of Cardiology. 2019 Sep 1;35(9):1079-81.

16. Joyce E. Frailty in advanced heart failure. Heart failure clinics. 2016 Jul 1;12(3):363-74.
17. Chaudhry SP, Stewart GC. Advanced heart failure: prevalence, natural history, and prognosis. Heart failure clinics. 2016 Jul 1;12(3):323-33.

18. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. Journal of the American College of Cardiology. 2010 Nov 2;56(19):1527-34.

19. Mullens W, Verbrugge FH, Nijst P, Tang WH. Renal sodium avidity in heart failure: from pathophysiology to treatment strategies. European heart journal. 2017 Jun 21;38(24):1872-82.

20. Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert opinion on drug discovery. 2017 Jan 2;12(1):61-88.

21. Xanthakis V, Enserro DM, Larson MG, Wollert KC, Januzzi JL, Levy D, Aragam J, Benjamin EJ, Cheng S, Wang TJ, Mitchell GF. Prevalence, neurohormonal correlates, and prognosis of heart failure stages in the community. JACC: Heart Failure. 2016 Oct 1;4(10):808-15.

22. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowski EA, Jessup M. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European journal of heart failure. 2016 Aug;18(8):891-975.

23. Kitsios GD, Mascari P, Etrunsi R, Gray AW. Co-administration of furosemide with albumin for overcoming diuretic resistance in patients with hypoalbuminemia: a meta-analysis. Journal of Critical Care. 2014 Apr 1;29(2):253-9.

24. Fang JC, Ewald GA, Allen LA, Butler J, Canary CA, Colvin-Adams M, Dickinson MG, Levy P, Stough WG, Sweitzer NK, Teerlink JR. Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. Journal of cardiac failure. 2015 Jun 1;21(6):519-34.

25. Jardim SI, dos Santos LR, Araújo I, Marques F, Branco P, Gaspar A, Fonseca C. A 2018 overview of diuretic resistance in heart failure. Revista Portuguesa de Cardiologia (English Edition). 2018 Nov 1;37(11):935-45.